drugset
drugset / Trial / NCT03228303

Nilotinib Versus Imatinib in Treatment of Patients With Newly Diagnosed Chronic Myeloid Leukemia

NCT03228303 ↗

Phase 0 Unknown 100 enrolled Assiut University
RandomizedParallel-groupSingle-blindTreatment

Summary

Nilotinib vs imatinib in patients with newly diagnosed CML-CP

Timeline

Start
2017-12-01
Primary completion
2020-07-30
Completion
2020-08-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Imatinib Small molecule 400 mg —
Comparator Nilotinib Small molecule 150 mg —

Indications

chronic myeloid leukemia